Biodeal Pharmaceuticals Raises INR 385Cr from RMB Capitalworks

Headquartered in Noida, Biodeal Pharmaceuticals Ltd. raised INR385 crore in a growth investment from RMB Capitalworks, a joint venture between Rand Merchant Bank and Capitalworks Group.

Anurag Kumar, CMD of Biodeal Pharmaceuticals, said the investment is a strong endorsement of the company’s capabilities built over two decades, particularly in specialty pharmaceuticals, nasal drug delivery, quality and manufacturing. He added that RMB Capitalworks was chosen as a long-term strategic partner for its operational expertise, governance approach and growth-oriented mindset, which align with Biodeal’s vision of building a globally competitive specialty pharmaceutical company and progressing towards a planned public listing.

The company said the investment will support its expansion across specialty pharmaceuticals, manufacturing capabilities and regulated markets. The capital will also be used to expand capacity and support growth in the US and European markets.

According to Anshuman Malur, Managing Partner, RMB Capitalworks, the firm’s investment in Biodeal is driven by the company’s differentiated position and growth potential, as well as Anurag’s founder-led approach. He said RMB aims to work closely with the Biodeal team on long-term value creation, with a focus on strengthening governance, supporting expansion and building the company into a leading pharmaceutical business. Malur added that healthcare remains a key investment focus for RMB.

Biodeal said it has recorded profitable growth over the past five years. Its FY26 revenue is estimated to grow by more than 60% year-on-year, with EBITDA margins also expected to expand. The company plans to continue expanding its specialty pharmaceutical business and work towards a planned public listing.